Difference between revisions of "Part:BBa K4307025"
m |
m |
||
Line 13: | Line 13: | ||
<!-- --> | <!-- --> | ||
− | < | + | <h2>Sequence and Features</h2> |
<partinfo>BBa_K4307025 SequenceAndFeatures</partinfo> | <partinfo>BBa_K4307025 SequenceAndFeatures</partinfo> | ||
Line 22: | Line 22: | ||
<!-- --> | <!-- --> | ||
− | + | <html> | |
+ | |||
<h2>Characterization </h2> | <h2>Characterization </h2> | ||
Line 28: | Line 29: | ||
<br> | <br> | ||
− | https://static.igem.wiki/teams/4307/wiki/wiki-parts-files/mainpage/bba-k4307025-gel.png< | + | <div class="center"> |
+ | <div class="thumb tnone"> | ||
+ | <div class="thumbinner" style="width:50%;"> | ||
+ | <a href="https://static.igem.wiki/teams/4307/wiki/wiki-parts-files/mainpage/bba-k4307025-gel.png" class="image"> | ||
+ | <img alt="" src="https://static.igem.wiki/teams/4307/wiki/wiki-parts-files/mainpage/bba-k4307025-gel.png" width="100%" height=auto class="thumbimage" /></a> <div class="thumbcaption"> | ||
+ | <div class="magnify"> | ||
+ | <a href="https://static.igem.wiki/teams/4307/wiki/wiki-parts-files/mainpage/bba-k4307025-gel.png" class="internal" title="Enlarge"></a> | ||
+ | </div> | ||
<b>Figure 1: </b> <b>The construction results of AffiPmrB.</b> | <b>Figure 1: </b> <b>The construction results of AffiPmrB.</b> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
<h2>References</h2> | <h2>References</h2> | ||
<p>[1] Chen, H. D., & Groisman, E. A. (2013). The biology of the PmrA/PmrB two-component system: the major regulator of lipopolysaccharide modifications. <i>Annu Rev Microbiol</i>, 67, 83-112.</p> | <p>[1] Chen, H. D., & Groisman, E. A. (2013). The biology of the PmrA/PmrB two-component system: the major regulator of lipopolysaccharide modifications. <i>Annu Rev Microbiol</i>, 67, 83-112.</p> | ||
<p>[2] Stahl, S., Graslund, T., Eriksson Karlstrom, A., Frejd, F. Y., Nygren, P. A., & Lofblom, J. (2017). Affibody Molecules in Biotechnological and Medical Applications. <i>Trends Biotechnol</i>, 35(8), 691-712.</p> | <p>[2] Stahl, S., Graslund, T., Eriksson Karlstrom, A., Frejd, F. Y., Nygren, P. A., & Lofblom, J. (2017). Affibody Molecules in Biotechnological and Medical Applications. <i>Trends Biotechnol</i>, 35(8), 691-712.</p> | ||
− | + | </html> | |
− | + | ||
− | + | ||
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display |
Revision as of 12:18, 13 October 2022
AffiPmrB
This part is modified from PmrB receptor in PmrB/A two-component system in E.coli. PmrB uses an iron (III)-binding motif to sense the environment(Chen & Groisman, 2013). The extracellular iron (III)-binding motif of pmrB receptor is replaced with another protein named affibody to construct this part. Affibody is a protein that can recognize Fc fragment of antibody(Stahl et al., 2017). This part is used to recognize the extracellular antibody signal and start the downstream signal transduction system.
In Tsinghua 2022 project, it was used in affipmrABC(BBa_K4307028) system.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BamHI site found at 855
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Characterization
The following figure demonstrates our successful construction.
References
[1] Chen, H. D., & Groisman, E. A. (2013). The biology of the PmrA/PmrB two-component system: the major regulator of lipopolysaccharide modifications. Annu Rev Microbiol, 67, 83-112.
[2] Stahl, S., Graslund, T., Eriksson Karlstrom, A., Frejd, F. Y., Nygren, P. A., & Lofblom, J. (2017). Affibody Molecules in Biotechnological and Medical Applications. Trends Biotechnol, 35(8), 691-712.